Report Highlights

U.S. Imaging Chemicals: Market Overview

The U.S. imaging chemicals market is a structurally diverse sector spanning four distinct application pillars: semiconductor photolithography, medical contrast and processing agents, commercial printing and reprographics, and legacy photographic film processing. Valued at USD 3.2 billion in 2024, the market has undergone a fundamental compositional shift over the past decade, with semiconductor and medical applications now collectively accounting for more than 60% of total demand. Government procurement through the Department of Defense and the Department of Veterans Affairs healthcare system underpins a significant and non-cyclical demand base that insulates the market from purely commercial fluctuations.

Private sector investment has led innovation in photoresist chemistry and contrast agent formulation, while federal and state regulatory frameworks have defined permissible chemistries, particularly in the elimination of certain halogenated compounds. The Environmental Protection Agency's Safer Choice Program has actively pushed formulators toward greener chemistries since 2012, reshaping product portfolios at Eastman Kodak, Carestream Health, and smaller specialty producers. The net effect is a market where regulatory compliance rather than raw material cost is the dominant competitive differentiator, especially for companies supplying hospitals, semiconductor fabs, and government printing facilities.

Policy-Driven Growth in U.S. Imaging Chemicals

The CHIPS and Science Act of 2022 (Public Law 117-167) is the single most consequential demand driver for semiconductor-grade imaging chemicals in the United States. The Act allocated USD 52.7 billion for domestic semiconductor manufacturing, with the CHIPS Program Office at the Department of Commerce administering USD 39 billion in fabrication incentives. Each new domestic fab requires metric tons of photoresists, anti-reflective coatings, and edge-bead removers annually. Intel's Fab 52 and Fab 62 in Chandler, Arizona, TSMC's Phoenix facility, and Samsung's Taylor, Texas plant collectively create a forward procurement pipeline that directly translates into confirmed volume growth for photoresist suppliers through 2030.

In medical imaging, the Centers for Medicare and Medicaid Services (CMS) reimbursement expansions under the Consolidated Appropriations Act of 2023 broadened coverage for advanced MRI and PET-CT procedures, directly increasing consumption of gadolinium-based and fluorine-18 radiopharmaceutical agents. Additionally, the National Institute of Biomedical Imaging and Bioengineering (NIBIB) allocated USD 1.4 billion in fiscal year 2024 grants for imaging technology development, incentivising new contrast agent formulations. The EPA's National Emission Standards for Hazardous Air Pollutants (NESHAP) for printing and publishing facilities simultaneously mandates reformulation of solvent-based printing chemicals, driving demand toward compliant water-based and UV-curable alternatives.

Regulatory Barriers and Compliance Costs

The Toxic Substances Control Act (TSCA), administered by the EPA's Office of Chemical Safety and Pollution Prevention, imposes rigorous pre-manufacture notification requirements for any new imaging chemical formulation. Manufacturers must submit a Pre-Manufacture Notice (PMN) at least 90 days before commercial production, during which the EPA may impose use restrictions or require additional testing under Section 5(e) orders. For complex photoresist chemistries, full TSCA compliance review, including risk evaluation under Section 6, extends timelines by 12 to 18 months and imposes compliance costs estimated at USD 250,000 to USD 800,000 per new substance, a barrier that effectively limits new entrants and consolidates the market among established players with dedicated regulatory affairs infrastructure.

For medical contrast agents, the FDA's Center for Drug Evaluation and Research (CDER) requires full New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) approval under 21 CFR Part 314, with gadolinium-based agents subject to additional Risk Evaluation and Mitigation Strategy (REMS) requirements following the FDA's 2018 safety communications on gadolinium retention. These REMS programmes impose label requirements, patient medication guides, and mandatory healthcare provider training, adding an estimated USD 1.2 million annually in compliance overhead per approved agent. Local content considerations also apply: semiconductor fab CHIPS Act incentive agreements include domestic supply chain expectations that pressure chemical suppliers to establish or expand U.S.-based manufacturing rather than import finished photoresists from Japan or South Korea.

Policy-Created Opportunities in U.S. Imaging Chemicals

The CHIPS and Science Act's Manufacturing USA programme, administered through the National Institute of Standards and Technology (NIST), funds the NIST Center for Neutron Research and associated materials characterisation programmes that create procurement demand for high-purity imaging chemicals in federal laboratory settings. More directly, the Defense Advanced Research Projects Agency (DARPA) Electronics Resurgence Initiative funds domestic photoresist R&D to reduce U.S. military dependence on Japanese extreme ultraviolet (EUV) resist suppliers, creating grant-backed opportunities for domestic specialty chemical companies willing to invest in advanced lithography chemistry. Suppliers positioned in the EUV photoresist segment stand to benefit from government co-investment that de-risks R&D expenditure.

In the environmental compliance segment, the EPA's Safer Choice and Design for the Environment (DfE) certification programmes create a distinct procurement advantage for certified imaging chemicals in federal agency purchasing under the Office of Federal Procurement Policy's sustainable acquisition mandate. Federal agencies are required under Executive Order 14057 (Catalyzing Clean Energy Industries and Jobs Through Federal Sustainability) to preference Safer Choice certified products, opening a direct government procurement channel. Simultaneously, state-level regulations in California under the Safer Consumer Products programme administered by the California Department of Toxic Substances Control are driving reformulation demand that, given California's market size, effectively sets national product standards for printing and photographic processing chemicals.

Market at a Glance

Leading Market Participants

• Eastman Kodak Company
• FUJIFILM Holdings America Corporation
• Carestream Health Inc.
• DuPont Electronics and Industrial
• Merck KGaA (EMD Electronics)
• Bracco Diagnostics Inc.
• GE HealthCare Technologies Inc.
• JSR Corporation (America)
• Shin-Etsu Chemical America Inc.
• Enviro Tech Chemical Services Inc.

Regulatory and Policy Environment

The primary legislative framework governing imaging chemicals in the United States is the Frank R. Lautenberg Chemical Safety for the 21st Century Act of 2016, which amended TSCA and significantly strengthened the EPA's authority to evaluate and restrict chemical substances. The EPA's Office of Chemical Safety and Pollution Prevention administers risk evaluations for high-priority substances under Section 6, with several imaging-relevant compounds, including certain glycol ethers used in photoresist formulations, currently under active review. The FDA's 21 CFR Part 314 and the REMS framework govern medical contrast agents, while the Nuclear Regulatory Commission (NRC) regulates radiopharmaceutical precursors used in PET imaging under 10 CFR Part 30. Compared to the European Union's REACH regulation, U.S. TSCA places a greater burden of proof on the EPA rather than manufacturers, but post-Lautenberg reforms have narrowed this distinction substantially.

Upcoming regulatory changes include the EPA's expected finalisation of risk management rules for cyclic aliphatic epoxide compounds used in UV-curable printing inks, anticipated in 2026, which will require reformulation across commercial printing chemical lines. The FDA is also expected to issue updated gadolinium retention guidance by 2026, potentially tightening REMS requirements for linear gadolinium agents and incentivising adoption of macrocyclic alternatives. California's Safer Consumer Products regulations targeting photographic processing chemicals are expected to expand their covered products list in 2025, forcing reformulation decisions that will propagate nationally. Relative to Canada and Japan, the U.S. regulatory framework is more enforcement-intensive but offers clearer safe harbour provisions for Safer Choice certified products, making certification a commercially strategic rather than merely ethical choice.

Long-Term Policy Outlook for U.S. Imaging Chemicals

By 2032, the U.S. imaging chemicals market will be increasingly defined by the intersection of domestic semiconductor policy and environmental chemical reform. The CHIPS Act's fabrication incentives are structured as multi-year agreements with performance milestones extending through 2030, ensuring that photoresist and process chemical demand from domestic fabs remains policy-supported rather than purely market-driven. DARPA's continued investment in next-generation lithography, including high-numerical-aperture EUV and nanoimprint lithography programmes, will progressively reshape the chemical specifications demanded by domestic fabs, creating both obsolescence risk for current photoresist formulations and premium-priced opportunity for suppliers who co-develop next-generation chemistries with federal research partners.

On the environmental and medical side, the EPA is widely expected to expand its Significant New Use Rules (SNURs) framework to cover a broader range of fluorinated compounds used in imaging applications, responding to growing per- and polyfluoroalkyl substance (PFAS) regulatory pressure. This will require substantial reformulation investment from suppliers of offset printing and industrial imaging chemicals before 2030. CMS reimbursement policy will continue to be the swing factor for medical contrast agent demand, with value-based care models under the Oncology Care Model and its successors likely to increase PET-CT utilisation and corresponding radiopharmaceutical chemical consumption. Companies that proactively align their product portfolios with anticipated EPA PFAS rules and FDA contrast agent guidance will capture disproportionate market share through 2032.